Evaluation of the immunohistochemical expression of HER2/NEU in urinary bladder neoplasms in a tertiary care hospital

Sukhmani Samra; Sarita Nibhoria; Vaneet Kaur Sandhu; Amandeep Singh

doi:10.18203/2320-6012.ijrms20231337

Authors

Sukhmani Samra Department of Pathology, GGS Medical College and Hospital, Faridkot, Punjab, India
Sarita Nibhoria Department of Pathology, GGS Medical College and Hospital, Faridkot, Punjab, India
Vaneet Kaur Sandhu Department of Pathology, GGS Medical College and Hospital, Faridkot, Punjab, India
Amandeep Singh Department of Surgery, GGS Medical College and Hospital, Faridkot, Punjab, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20231337

Keywords:

HER2/NEU, High-grade, IHC, Low-grade, PUNLMP, Urinary bladder neoplasms

Abstract

Background: HER2/NEU expression in urothelial neoplasms has been reported to range from 9% to 80% on immunohistochemistry. We studied the expression of HER2/NEU in urothelial neoplasms and its variability according to histological grade along with the prognostic value.

Methods: The present study was conducted on 60 formalin-fixed, paraffin-embedded specimens of urinary bladder neoplasms, which comprised 45 cases of high-grade urothelial carcinoma followed by 13 cases of low-grade and 2 cases of PUNLMP. These were then subjected to IHC by HER2/NEU. Membrane positivity for HER2/NEU was noted.

Results: A total of 65% of cases showed positive membranous HER2/NEU expression. HER2/NEU expression was noted in 82.6% of cases of high grade while 8.4% of cases of low grade were positive for HER2/NEU expression.

Conclusions: The majority of high grade invasive urothelial carcinomas showed positive HER2/NEU expression with a significant p-value <0.001. Thus patients with high grade urothelial carcinoma may benefit from HER2/NEU targeted therapy.

Metrics

Metrics Loading ...

References

Saginala K, Barsouk A, Aluru SJ, Rawla P, Padala AS, Barsouk A. Epidemology of bladder cancer. Med Sci. 2020;13:15.

Andersonn K, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev. 2004;84:935-86.

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bary F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71:96-108.

Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, et al. Bladder cancer, version. J Natl Compr Canc Netw. 2017;15:1240-67.

Scherrer E, Kang A, Bloudek LM, Koshkin VS. HER2 expression in urothelial carcinoma, a systematic literature review. Front Oncol. 2022;12:1011885.

Miyazaki J, Nishiyama H. Epidemology of urothelial carcinoma. Int J Uro. 2017;24:730-4.

Rozanec JJ, Secin FP. Epidemiology, etiology and prevention of bladder cancer. Arch Esp Urol. 2020;73:872-8.

Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci. 2020;8:15-9.

Sharma M, Goswami KC, Gupta S. Urinary Bladder Carcinoma: A clinicopathological study. Int J Sci Res. 2017;6:46-7.

Mishra V, Balasubramaniam G. Urinary bladder cancer and its associated factors an epidemiological overview. Indian J Med Sci. 2021;73:239-48.

Agher N, Tou A, Larbaoui B, Moulessehoul S. Urothelial carcinoma study of expression and amplification of human epidermal growth factor receptor 2 (her-2/neu) in Sidi Bel Abbes, Algeria. J Dis Glob Health. 2018;11:36-41.

Gonzalez E, Castro LN, Sierra J, Casas M, Luisa M, Gonzalez V, et al. Bladder carcinoma data with clinical risk factors and molecular markers: a cluster analysis. Biomed Res Int. 2015;2015:168682.

Kumar S, Prajapati O, Vaiphei K, Parmar KM, Sriharsha AS, Singh SK. Human epidermal growth factor receptor 2/neu overexpression in urothelial carcinoma of the bladder and its prognostic significance: Is it worth hype? South Asian J Cancer. 2015;4:115-7.

Ochi MR, Oukabli M, Bouaiti E, Chahdi H, Boudhas A, Allaoui M, et al. Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma. BMC Clin Pathol. 2017;17:3.

Ibrahim BB, Mahmoud AS, Mohamed AA, Hanbuli HM. Expression of HER2/NEU and ki-67 in urothelial carcinoma and their relation to clinicopathological data: an Egyptian study. J Clin Diagnostic Res. 2021;15:6-9.

Rosli N, Mahasin M, Saleh MFM, Shukor AN. The prognostic significance of HER2 expression in urothelial carcinoma. Malays J Pathol. 2022;44:245-52.

Danaei S, Madani SH, Khazaei S, Izadi B, Saleh E, Sajadimajd S. The survey of HER2/NEU expression and it’s correlation with some pathological factors in urothelial bladder tumors. Iran Red Crescent Med J. 2018;20:34-9.

Agarwal M, Jaiswal M, Pandey S, Fareed R. HER2/Neu expression in urinary bladder cancer: histopathological, clinico-radiological and epidemiological aspects. Indian J Pathol Oncol. 2019;6:489-96.

Charfi S, Khabir A, Mnif H, Ellouzea S, Mhiri MN, Boudawara ST. Immunohistochemical expression of HER2 in urothelial bladder carcinoma and its correlation. J Microsc Ultrastruct. 2013;1:17-21.